In this episode, Anousha is joined by Dr. Su Wang, Medical Director of the Chinese Medical Program at Cooperman Barnabas Medical Center and Medical Advisor to the Hepatitis B Foundation, along with Dr. Thomas Tu, Molecular Biologist at the Westmead Institute for Medical Research in Australia. Together, they discuss expanding hepatitis B treatment guidelines by broadening eligibility criteria, improving access, reducing loss to follow-up, and the importance of including public health and patie...
All content for B Heppy is the property of Hepatitis B Foundation and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, Anousha is joined by Dr. Su Wang, Medical Director of the Chinese Medical Program at Cooperman Barnabas Medical Center and Medical Advisor to the Hepatitis B Foundation, along with Dr. Thomas Tu, Molecular Biologist at the Westmead Institute for Medical Research in Australia. Together, they discuss expanding hepatitis B treatment guidelines by broadening eligibility criteria, improving access, reducing loss to follow-up, and the importance of including public health and patie...
In this episode, Bright and Anousha are joined by researchers Philippa Mathews and Louise Downs to discuss their latest findings on the devastating financial impact of hepatitis B on patients and their families. They unpack key insights from their recent paper, shedding light on the hidden costs of care. The episode also features a powerful segment from patient advocate Joy Koy, who shares a firsthand perspective on the economic burden of living with hepatitis B. Support the show Our website:...
B Heppy
In this episode, Anousha is joined by Dr. Su Wang, Medical Director of the Chinese Medical Program at Cooperman Barnabas Medical Center and Medical Advisor to the Hepatitis B Foundation, along with Dr. Thomas Tu, Molecular Biologist at the Westmead Institute for Medical Research in Australia. Together, they discuss expanding hepatitis B treatment guidelines by broadening eligibility criteria, improving access, reducing loss to follow-up, and the importance of including public health and patie...
